Ivím Health review

One thing here is genuinely unusual and belongs first. This provider has published outcomes from its own patients in a peer-reviewed journal, and footnotes them as retrospective observational studies rather than dressing them up as trial evidence. Almost every provider reviewed on this site substantiates its results with testimonials, or with percentages borrowed from trials of a different product entirely — something two sellers here do with compounded preparations that were never trialed. Publishing your own data, correctly labeled as observational, is a different standard, and it should count. The pricing is more ordinary than the evidence. The headline tirzepatide rate is attached to six months bought together, and no month-to-month figure sits beside it, so the cheap number asks a reader to commit half a year before they know whether the medication suits them at all — which for a first-time patient is exactly the wrong way round. There is no dose behind the figure either. On the useful side, the approved oral GLP-1 is carried alongside the compounded injectable, and same-day provider access is stated rather than implied.

Vs median

$36/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Varies by dose, plan or tier

Price last updated

August 2026

Ivím Health dispenses through a Not named facility. No bloodwork is required before you start. A clinician review is included in the price.

One thing here is genuinely unusual and worth stating first: this provider has published outcomes from its own patients in a peer-reviewed journal, and footnotes them as retrospective observational studies rather than presenting them as trial evidence. Almost every provider reviewed on this site substantiates its results with testimonials or with figures borrowed from trials of a different product; publishing your own data, correctly labeled as observational, is a different standard entirely and it should count for something. The pricing is more ordinary. The headline tirzepatide rate is attached to six months bought together, and no month-to-month figure sits beside it, so the cheap number requires committing half a year before anyone knows whether the medication suits them — which for a first-time patient is the wrong way round. There is no dose behind the figure either. The Wegovy pill is carried as well, which gives a reader an approved oral route alongside the compounded injectable, and same-day provider access is stated rather than implied.

The published rate requires a six-month commitment, with no month-to-month figure beside it.

• No dose is published behind the figure.
• Peptide therapies are advertised as coming soon rather than available.

Ivím Health is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• The true annual cost of a plan
• Titration planner